Change in troponin concentrations in patients with macrotroponin: An in vitro mixing study

Cardiac troponins: Mechanisms of release and role in healthy and diseased subjects

“…These cTnAABs in presence of their targets (cTnI or cTnT) can make a complex known as macrotroponin. 107 Several studies showed that cTnAABs masking the critical cTns epitopes recognized by antibody used in current commercial hs-assays can help to generate false negatives at analytical tests. 107,108 Lam et al found that the analytical interference of cTnAABs is more serious in cases of macrotroponin that involves cTnI compared to cTnT.…”

“…A further condition that may lead to difficulties in cTns measurement in the blood is represented by the presence of the endogenous troponin autoantibodies (cTnAABs). These cTnAABs in presence of their targets (cTnI or cTnT) can make a complex known as macrotroponin 107 . Several studies showed that cTnAABs masking the critical cTns epitopes recognized by antibody used in current commercial hs‐assays can help to generate false negatives at analytical tests 107,108 .…”

“…107 Several studies showed that cTnAABs masking the critical cTns epitopes recognized by antibody used in current commercial hs-assays can help to generate false negatives at analytical tests. 107,108 Lam et al found that the analytical interference of cTnAABs is more serious in cases of macrotroponin that involves cTnI compared to cTnT. The authors suggested that the highly variability of cTnI levels among individuals could be related to the presence and ability of cTnAABs to create macrotroponin in the blood.…”

“…The authors suggested that the highly variability of cTnI levels among individuals could be related to the presence and ability of cTnAABs to create macrotroponin in the blood. 107 The use of several techniques for protein analysis allowed to understand that cTnI and cTnT can be found in the blood either as cTns complex, as intact proteins, or degradation protein products. 62 By the use of western blot analysis, Madsen et al observed in a group of 26 male patients with acute STEMI, treated with thrombolytic drugs, that intact cTnI and a single degradation product (24 and 20 kDa, respectively) were detectable as early as 90 min after onset of symptoms with further degradation (up to 7 degradation products) after 165 min.…”

“…Lam et al found that the analytical interference of cTnAABs is more serious in cases of macrotroponin that involves cTnI compared to cTnT. The authors suggested that the highly variability of cTnI levels among individuals could be related to the presence and ability of cTnAABs to create macrotroponin in the blood 107 …”